A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia

Trial Profile

A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 21 Jul 2017 According to Sunovion Pharmaceuticals media release, based on the results of this study Health Canada approved the Supplemental New Drug Submission (SNDS) for Latuda (lurasidone HCI) for the management of the manifestations of schizophrenia in adolescents aged 15 to 17 years.
    • 24 May 2017 Preliminary data on the long-term effectiveness of lurasidone in adolescents with schizophrenia; results presented at the 170th Annual Meeting of the American Psychiatric Association
    • 24 May 2017 Interim analysis of a 24-month, open-label extension study; results presented at the 170th Annual Meeting of the American Psychiatric Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top